Marketing authorisation application for semaglutide for weight management submitted to the European Medicines Agency

The potential indication for the once-weekly GLP-1 analogue is for the treatment of adults with obesity or who are overweight, with at least one weight-related comorbidity. The submission is based on data from the STEP phase 3a trial programme.

Source:

PharmaTimes